Cleerly Brought $192M in Series C Funding

Cleerly, Inc., a New York-based startup, has announced a successful Series C funding which brought in $192 million, effectively quadrupling their previous funding.

The company is developing artificial intelligence capable of predicting heart attacks. The investment came after the company proved their noninvasive solution is on par with the current gold standard of coronary angiography in spotting signs of heart disease. The funding will help Cleerly in their efforts to bring the technology global.

Cleerly intends to direct the money towards building out their team, expanding the commercial reach of their software, and supporting more than a dozen ongoing clinical trials to further back up the technology’s claims.

The Series C funding round was led by T. Rowe Price Associates, T. Rowe Price Investment Management and Fidelity Management and Research Company. This large infusion follows shortly after a Series B funding round announced in June, which brought in $43 million.

The software analyzes noninvasive CT angiography scans of the heart to both characterize and measure the amount of plaque built up in the arteries. By evaluating the likelihood that those build-ups could completely cut off the supply of oxygen to a patient’s heart, the software is able to identify early signs of heart disease and calculate the risk that a patient will experience a heart attack.

The system is powered by a database of millions of previously assessed CT images, as well as data collected in clinical trials spanning thousands of patients. Cleerly is aiming to further expand that repository with its ongoing studies, which plan to enroll more than 100,000 patients from across the globe within the next decade.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts